Compare Incyte Corporation (INCY) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Yum China Holdings Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Yum China Holdings Inc trades at $42.88 (market cap $14.11B). The key difference: Incyte Corporation is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.78% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Yum China Holdings Inc for 77 Days on average.
| INCY | YUMC | |
|---|---|---|
Market Cap | $22.85B | $14.11B |
Volume | 1,927,029 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $57.95 |
52-Week Low | $83.80 | $39.98 |
Typical Hold Time | 33 Days | 77 Days |
Enterprise Value | $18.35B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
YUMC trades at $42.99, up 5.76% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 73.68% analyst buy consensus highlight positive momentum. The company completed the Pizza Hut China brand acquisition and expanded its Burger Bar concept, signaling growth initiatives. Cash flow from operations remains robust at $1.47B for 2025, though net cash flow is negative due to financing activities.
The outlook is mixed: solid earnings growth and expansion potential support upside, but technical weakness and competitive pressures pose risks. Investors should weigh the attractive valuation (P/E 15.3) against near-term price volatility and market sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
